Novo Nordisk is partnering with the digital obesity clinic Eatit to raise awareness of obesity and promote prevention in Swedish healthcare. The weight loss industry had a turnover of $224 billion in 2021 and is predicted to reach $405 billion in 2030.
But the industry is being fundamentally transformed by effective medicines that are changing the way obesity is treated.
The winners look set to be the pharmaceutical companies and the digital players that can partner with pharmaceutical companies.
So far, lifestyle changes have had little impact and many non-healthcare providers have been able to sell treatments or diets that have no long-term effects.
Since the launch of the Novo Nordisk drug Wegovy on the US market, all players in the weight loss industry have had to adapt.
Weightwatchers has therefore acquired the digital obesity clinic Sequence in the US for $132 million, increasing Weightwatchers’ parent company’s stock by 60%.
Investors understand that the weight loss industry is in turmoil and that those who are fastest to adapt get investors’ interest.
Eatit is Sweden’s largest online dietitian clinic for the treatment of obese patients.
The platform enables healthcare providers to give a standardized dietician treatment.
Among other things, the service saves healthcare professionals time as they do not have to develop their own treatments, and treatment results can also be continuously evaluated and improved.
Dietitians, who specialize in obesity and CBT treatment, can meet more patients through effective interactive online work. “The collaboration includes a development project with the aim of strengthening preventive efforts in collaboration with the healthcare system to achieve improved health, as well as increasing knowledge about the disease through interaction on Eatit’s and Novo Nordisk’s digital platforms,” says Theresia Silander Hagström, CEO and co-founder of Eatit.
Novo Nordisk recently issued a press release about the collaboration with Eatit to increase patients’ knowledge and support to make lifestyle changes.
This is where Eatit comes in to make sure patients get the support they need. “We share a common vision of reducing the risk of secondary diseases through preventive measures and thus contribute to sustainable health.
We want to do this by increasing knowledge about obesity and reinforcing the importance of long-term functional diet and lifestyle habits.
There are currently shortcomings in knowledge about and treatment of obesity.
With this collaboration, we want to help ensure that people living with the disease can be given the opportunity to come into contact with dieticians as a support for improved health”, says Madeleine Wallding, Business Area Manager at Novo Nordisk Sweden.
See press release here See information about Eatit For more information: Johan Bloom, CEO Curus [email protected],+46 733 64 84 90 Erik Olsson, Investment Manager [email protected],+46 708 37 73 54